UBS analyst Danielle Antalffy lowered the firm’s price target on Sight Sciences (SGHT) to $5 from $5.50 and keeps a Buy rating on the shares.

Thales has revealed that it has already sold thousands of its Xtraim weapon sights, including sales late in-2024, and that it is now in service with two NATO countries along with one country in the ...

This presents a challenge, however, given the multitude of vaccine approaches currently being tested and the even greater number of vaccine target antigens being evaluated. In a recent report by ...

Analysts have recently evaluated Sight Sciences and provided 12-month price targets. The average target is $4.72, accompanied by a high estimate of $5.50 and a low estimate of $3.00. Experiencing a 20 ...